Anemia constitutes a major global health burden, and iron deficiency is the most common cause of it. Iron deficiency and replacement affect not only hemoglobin (Hb) levels but also other hematological parameters such as platelet count. In this mini-review, we explore thrombocytopenia as a side effect of iron replacement therapy. We searched for relevant articles published in English, and all case reports/series of iron-induced thrombocytopenia were collected and analyzed. A total of 11 case reports and one case series were found relating to very low Hb at a baseline level of 5.25 +/- 2.2 g/dl and variable platelet count at baseline that dropped in 9 +/-3 days to an average of 121 +/- 112 x 10⁹/L, which in most of the cases was self-corrected. The parenteral route was more commonly reported to be associated with thrombocytopenia, and discontinuation of therapy was needed in two patients. The mechanisms, prevalence, and clinical significance of thrombocytopenia associated with iron replacement are unknown; several effects of iron on the primary hematopoietic cells and stromal cell lines have been proposed, such as influence on common progenitors, effects on cytokines, and thrombopoietic effect of erythropoietin, which is directly affected by iron levels. Iron replacement can lead to significant thrombocytopenia. Further research is needed to describe the exact incidence, mechanism, and clinical significance of thrombocytopenia associated with iron supplementation.

Gastrointestinal manifestations of leukemias have been well recognized. Typically, acute leukemias cause typhlitis or appendicitis more commonly than chronic leukemias. Our case points to appendicitis as possible manifestation of chronic myelogenous leukemia.

To optimize care for patients with hemoglobinopathies, frequent screening for COVID‐19 is prudent as viral kinetics in asplenic patients are unknown and differentiating prolonged viral shedding versus reinfection remains a challenge.

Extramedullary hematopoiesis (EMH) is a well‐known complication of beta thalassemia major and frequently occurs in typical sites such as liver or spleen. However, when presenting in unusual sites as sacrum, other diagnosis should be excluded by histopathology prior to deciding on treatment plan.

Introduction Breast cancer is a major health concern and is the most common cancer in women according to the American Cancer Society with 1 in 3 women diagnosed each year. Breast cancer screening with annual or biennial mammography for women 40 years and older has significantly decreased mortality. Our aim in this study is to assess factors predicting and affecting adherence to breast cancer screening in the United States, consequently recognizing where and how an intervension is required. Methods A retrospective analysis was conducted of adult women using the 2021 National Health Interview Survey (NHIS). Data that was analyzed and recorded included age, race, anxiety, BMI, smoking status, region, education level, residence location, health insurance, self-rated health status, pay for mammogram, and mammogram within 2 years. Results Data from 6334 women between 50 and 74 of age was analyzed. 4583 women (72.8%) had a mammogram within the past two year while 1751 (27.2%) had notscreening was not affected by age as 27.8% of women between 50–64 and 26.2% of women between 65–74 did not have a mammogram (P value = 0.223), or by region (P value = 0.176). However, adherenece to screening varied significantly by race (P value < 0.0001), BMI (P value = 0.02), level of education (P value < 0.0001), insurance status (P value < 0.0001), smoking status (P value = 0.0001), and place of residence (P value = 0.002). Conclusion Breast cancer screening has substantial role in reducing morbidity and mortality from the disease. Further interventions are still needed to assess factors preventing women from undergoing screening and assist in addressing such factors.